Last reviewed · How we verify
A Phase I Safety Study of Farletuzumab (MORAb-003), Carboplatin and Pegylated Liposomal Doxorubicin (PLD) in Subjects With Platinum-sensitive Ovarian Cancer
The purpose of this study is to evaluate whether combination therapy with farletuzumab (MORAb-003), carboplatin, and pegylated liposomal doxorubicin (PLD) is safe.
Details
| Lead sponsor | Morphotek |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 15 |
| Start date | 2009-11 |
| Completion | 2012-10 |
Conditions
- Epithelial Ovarian Cancer
Interventions
- Farletuzumab, Carboplatin, and PLD
Primary outcomes
- To assess the safety of the combination of farletuzumab, carboplatin, and PLD in subjects with platinum-sensitive ovarian cancer. — At all study visits.
Countries
United States